None listed
Conditions
Interventions
Group 1 Type of group
Patients will take Valsartan 80 mg orally, once a day, at the same time every day (between 6 a.m. and 10 a.m.), except for the days when a clinical visit is scheduled. This will be done for 4 weeks.
Those patients after 4 weeks have not achieved adequate control of their blood pressure, will stop Valsartan and begin with HYZAAR (Losartan 50mg / HCTZ 12.5 mg) orally, once a day, at the same time every day (between 6 a.m. and 10 a.m.) except for the days when a clinical visit is scheduled. Thi
Sponsors
MERCK & CO.INC.,
Eligibility
Inclusion criteria
Inclusion criteria: a. Between 18 and 75 years of age. b. Sex: Both male and female patients are acceptable. c. Hospitalization status: Outpatient. d. The patient suffers from essential hypertension. e. Patients must have grandparents by their mother or father / biological parents of patients born in Asia. f. Blood pressure • At visit 1 with a SiDBP> 85 to <95 mmHg. • In visit 2 that show a SiDBP between 95 and 115 mmHg • At Visit 3 only patients who are not controlled will be switched to HYZAAR ™. g. The patient is legally capable and can understand the nature and implications of the clinical study. h. The patient wants to participate in this study.
Exclusion criteria
Exclusion criteria: a) The patient is pregnant or is breastfeeding. b) The patient has known or suspected secondary hypertension. c) The patient has a history of malignant hypertension. d) The patient has a systolic blood pressure while sitting (SiSBP)> 190 mmHg. e) The patient has a history of stroke f) Patients with a history of myocardial infarction within the last 6 months. g) Patient with active history of angina that has not stabilized with medical therapy. h) Patients who have undergone percutaneous coronary intervention or aortocoronary bypass surgery within the previous 6 months. i) Patients with atrioventricular block (second or third degree). j) Patients with complete blockage of the left fascicular branch. k) Patients with atrial fibrillation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Clinical measurement of SiDBP Measure:Efficacy of HYZAAR ™ (Losartan 50 mg / HCTZ 12.5 mg): Average change in diastolic pressure while the patient is sit (SiDBP) Timepoints:At the 4th week of treatment with HYZAAR ™ (Losartan 50 mg / HCTZ 12.5 mg) | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:Clinical measurement of SiSBP Measure:Efficacy of HYZAAR ™ (Losartan 50 mg / HCTZ 12.5 mg): Change averaged with respect to the baseline sistolic pressure while the patient is sitting (SiSBP) Timepoints:At the 4th week of treatment with HYZAAR ™ (Losartan 50 mg / HCTZ 12.5 mg) ; Outcome name:Clinical measurement of SiDBP Measure:Efficacy of HYZAAR ™ (Losartan 50 mg / HCTZ 12.5 mg): Proportion of patients reaching the goal (minimum mean diastolic blood pressure with the participant sitting <90 mmHg) Timepoints:At the 4th week of treatment with HYZAAR ™ (Losartan 50 mg / HCTZ 12.5 mg) ; Outcome name:Clinical evaluation Measure:Safety of Valsartan of 80 mg and HYZAAR ™ (Losartan 50mg / HCTZ 12.5mg): Incidence of adverse events (AD) and adverse reactions (AD related to the drug) in each treatment period. Timepoints:At the time of presentation | — |
Countries
Peru
Contacts
Public ContactStela Lopez
MERCK SHARP & DOHME PERU S.R.L
Outcome results
None listed